BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2016 6:56:00 PM | Browse: 1442 | Download: 2699
 |
Received |
|
2016-06-27 09:59 |
 |
Peer-Review Started |
|
2016-06-27 15:04 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2016-08-03 08:33 |
 |
Revised |
|
2016-08-23 02:45 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2016-09-09 17:42 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2016-09-14 13:02 |
 |
Articles in Press |
|
2016-09-14 13:02 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-11-14 17:10 |
 |
Publish the Manuscript Online |
|
2016-11-26 18:57 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Infliximab does not increase colonic cancer risk associated to murine chronic colitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Loris R Lopetuso, Valentina Petito, Tiziano Zinicola, Cristina Graziani, Viviana Gerardi, Vincenzo Arena, Maria Emiliana Caristo, Andrea Poscia, Giovanni Cammarota, Alfredo Papa, Valerio Cufino, Alessandro Sgambato, Antonio Gasbarrini and Franco Scaldaferri |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Crohn’s and Colitis Foundation of America, Research Fellowship Award |
CON125252 |
|
| Corresponding Author |
Dr. Franco Scaldaferri, Gastroenterology Division, Catholic University of Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy. francoscaldaferri@gmail.com |
| Key Words |
Inflammatory bowel disease; Ulcerative colitis; Colorectal cancer; Infliximab; AOM-DSS model; Cancer on chronic colitis |
| Core Tip |
We report our results on the potential role of Infliximab on cancer progression in AOM-DSS murine model of colorectal cancer associated to chronic colitis. AOM/DSS model was induced in C57BL/6 mice. Mice were injected with Infliximab during each DSS cycle while control mice received saline. Mice were sacrificed at week 10 and colons were analyzed macroscopically and microscopically for number of cancers and degree of inflammation. MTT assay was performed on CT26 to evaluate the potential influence of Infliximab (IFX) role on metabolic activity and proliferation. This study demonstrates that beside its well-known healing capacity, IFX does not increase proliferative cancer cells ability and colorectal cancer risk in AOM-DSS model of tumor on chronic colitis. |
| Publish Date |
2016-11-26 18:57 |
| Citation |
Lopetuso LR, Petito V, Zinicola T, Graziani C, Gerardi V, Arena V, Caristo ME, Poscia A, Cammarota G, Papa A, Cufino V, Sgambato A, Gasbarrini A, Scaldaferri F. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol 2016; 22(44): 9727-9733
|
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i44/9727.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i44.9727 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.